Financière de Tubize S.A.
TUB
Classifica tra le azioni
#2203
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Prezzo delle azioni
$203.04
Ultima sincronizzazione: 2026-10-21
Capitalizzazione di mercato
$9.04B
Variazione (1 giorno)
-7.47%
Variazione (1 anno)
-22.97%
Paese
BE
Scambia Financière de Tubize S.A. (TUB)
Categoria
Healthcare
Ricavi di Financière de Tubize S.A. (TUB)
Ricavi nel Jun 2026 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Financière de Tubize S.A., i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2023, l'azienda ha registrato ricavi di 0.00 una diminuzione rispetto a i ricavi dell'anno 2022, che erano pari a $8.74K. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Financière de Tubize S.A. da 2003 a 2026
Ricavi alla fine di ogni anno
| Anno | Ricavi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | $13.79K | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $8.74K | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | -100.00% |
| 2019 | $4.49K | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | -100.00% |
| 2016 | $317.76K | 29,164.42% |
| 2015 | $1.09K | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $2.71K | 0.00% |
| 2003 | 0.00 | 0.00% |
Ricavi di aziende simili o concorrenti
| Azienda | Ricavi | Differenza nei ricavi | Il paese |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
